key: cord-0943875-tcuyjjmz
authors: Klopfenstein, Timothée; Tipirdamaz, Can; Gendrin, Vincent; Osman, Molka; Mercier, Julien; Bouvier, Elodie; Bouiller, Kevin; Lepiller, Quentin; Toko, Lynda; Pierron, Alix; Royer, Pierre-Yves; Garnier, Pauline; Kadiane-Oussou, N'dri-Juliette; Chirouze, Catherine; Zayet, Souheil
title: Third of patients have gustatory dysfunction 9 months after SARS-CoV-2 infection: the ANOSVID study
date: 2022-03-30
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.03.053
sha: 7d735ee0b8810d7df9f291233ca5cf9e160fba4f
doc_id: 943875
cord_uid: tcuyjjmz

nan

Dear Editor, 38 Olfactory and/or gustatory dysfunctions (OGD) are specific symptoms of COVID-19 (Salmon 39 Ceron et al., 2020) . Olfactory (OD) dysfunction have drawn considerable attention in the 40 beginning of the pandemic, more than gustatory dysfunction (GD) (Klopfenstein et al., 2020; 41 Parma et al., 2020) . However, OGD's impact on quality of life seems to be majority due to 42 GD (Coelho et al., 2021) which is defined as partial (hypogeusia) or complete (ageusia) loss 43 of taste, or alteration or distortion in the perception of taste (dysgeusia). Questions about 44 COVID-19 GD remain, especially GD duration and the proportion of patients with persistent 45 GD (Hopkins et al., 2021) . In this work we describe persisting GD in patients with confirmed 46 SARS-CoV-2 infection.

ANOSVID (Zayet et al., 2021b) , an observational retrospective study in Nord Franche-Comté 48 Hospital, France; was designed in accordance with the declaration of Helsinki and was 49 conducted in accordance with French legislation. We included all adult inpatients and 50 outpatients (≥ 18 years old) with a diagnosis of COVID-19 confirmed by RT-PCR on 51 respiratory samples from March 1st, 2020, to May 31st, 2020. Patients' consent was collected 52 by phone calls and then filled in an online questionnaire. The persistence of GD was defined 53 by the presence (at the date of questionnaire responses) of any GD related to SARS-CoV-2 54 infection, and which was not present before SARS-CoV-2 infection. Patients who related a 55 final date for GD due to SARS-CoV-2 infection before relapse were considered to have a 56 "recurrence of symptoms" after an asymptomatic period. Patients who had a persistence of 57 symptoms since the beginning of SARS-CoV-2 infection (without an asymptomatic period) 58 were considered to have "continuous symptoms". Data was collected during the first quarter 59 of 2021.

During the study period (Zayet et al., 2021b) p=0.001), total bilirubin (9.6 3.0 µmol/L versus 13.5 8.3 µmol/L respectively, p=0.02) and 87 haemoglobin (13.1 1.5 g/dL versus 14.0 1.5 g/dL respectively, p=0.04) were lower in p-GD 88 group than r-GD group. No other significant differences were found about clinical and 89 biological findings and no significant differences were found about sex, age, comorbidities, 90 imaging findings and outcome.

Nine months after COVID-19 GD, hypogeusia is present in 29% of cases (62/214) while 92 ageusia is scarce, 0.01% of cases (2/214), this kind of heterogeneous and (sometimes) long 93 recovery timeline has been described (Bussière et al., 2021; Riestra-Ayora et al., 2021) . The 94 more likely explanation is that the damage to the olfactory/ gustatory epithelium varies 95 between cases, and extensive damage will take a longer time to regenerate than focal lesions 96 (Butowt et al., 2021; Thakur et al., 2021 ).

Gustative disorders were self-reported which are the main limitation of ANOSVID as most of 98 studies on this topic (2-8). Furthermore, patients with persistence GD presented rather 99 "symptoms recurrences" than "continuous symptoms" and confounding factors responsible of 100 GD could explain a part of these results; for example, other viral infection with nasal 101 obstruction or COVID-19 re-infection (but it seem to be scarce at this period (Zayet et al., 102 2021a)); however, on another hand these episodes of GD recurrences could be linked to the 103 persistence of the virus in a reservoir (sanctuary site) with viral rebound (Zayet et al., 2021a) , 104 as suggested for other viral infections (Zayet et al., 2021a) . relationships that could have appeared to influence the work reported in this paper. 128

The authors declare no conflicts of interest. 

Chemosensory Dysfunctions Induced by 133 COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers

The olfactory nerve is not a 136 likely route to brain infection in COVID-19: a critical review of data from humans and 137 animal models

Quality 140 of life and safety impact of COVID-19 associated smell and taste disturbances

Six month follow-up of self-reported loss of smell during the COVID-19 pandemic

Features of anosmia in COVID-19

More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell

Long-term follow-up of olfactory and 169 gustatory dysfunction in COVID-19: 6 months case-control study of health workers

Self-reported loss of 177 smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia 178 cohort study

COVID-19 185 neuropathology at Columbia University Irving Medical Center

188 Recurrence of COVID-19 after recovery ? A case series in health care workers

Microbes Infect. 23, 104803

Post-193 COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 194 Patients: Data from the First Wave of COVID-19 in

Gustatory recovery over time in the ageusia (n=141) or hypogeusia (n=73) groups or total patients 199 (n=214) after SARS-CoV-2 infection